

# Accepted Manuscript

Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future

Daniel W. Sherbenou, Tomer M. Mark, Peter Forsberg

PII: S2152-2650(17)30277-X

DOI: [10.1016/j.clml.2017.06.030](https://doi.org/10.1016/j.clml.2017.06.030)

Reference: CLML 964

To appear in: *Clinical Lymphoma, Myeloma and Leukemia*

Received Date: 15 March 2017

Accepted Date: 8 June 2017

Please cite this article as: Sherbenou DW, Mark TM, Forsberg P, Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future, *Clinical Lymphoma, Myeloma and Leukemia* (2017), doi: 10.1016/j.clml.2017.06.030.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Title: Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future**

**Authors: Daniel W. Sherbenou,<sup>1</sup> Tomer M. Mark,<sup>1</sup> Peter Forsberg<sup>1</sup>**

**Affiliations:**

<sup>1</sup>Division of Hematology, University of Colorado – Anschutz Medical Campus, 1665 Aurora Court, MS F754, Aurora, CO 80045, USA

**Corresponding author:**

Daniel W. Sherbenou, MD, PhD

Division of Hematology, University of Colorado – Anschutz Medical Campus, 12700 E 19th Ave, Box B170, Aurora, CO 80045, USA

**Tel:** (303) 724-9520 **Fax:** (303) 724-7217 **Email:** daniel.sherbenou@ucdenver.edu

**Running title:** Monoclonal Antibodies in Multiple Myeloma

**Journal:** Clinical Lymphoma, Myeloma and Leukemia

**Article type:** Review

**Abstract work count:** 192

**Body text word count:** 5,019

**Tables/Figures:** 2/2

**References:** 103

**Disclosures:**

T.M. discloses a consulting or advisory role and travel for Takeda, Celgene, and Amgen; research funding from Celgene and Amgen. P.F. discloses research funding from Abbvie. D.S. discloses research funding from Merck.

The authors listed above are solely responsible for the writing of this manuscript.

Download English Version:

<https://daneshyari.com/en/article/5581718>

Download Persian Version:

<https://daneshyari.com/article/5581718>

[Daneshyari.com](https://daneshyari.com)